457-87-4

Usage

InChI:InChI=1/C11H17N/c1-3-12-10(2)9-11-7-5-4-6-8-11/h4-8,10,12H,3,9H2,1-2H3

Upstream product

• 75-04-7 ethylamine 
• 103-79-7 1-phenyl-acetone 
• 627-45-2 N-formylethylamine 
• 908094-04-2 phenyldiazomethane 
• 109-89-7 diethylamine 
• 705-60-2 (2-nitroprop-1-enyl)benzene 
• 22560-16-3 lithium triethylborohydride 
• 59313-90-5 N,N-diethyl-1-methyl-2-phenylethylamine 
• 17322-34-8 (2-nitropropyl)benzene 
• 119290-77-6 N-ethyl-N-methylamphetamine 

Downstream Products

• 102175-69-9 ethyl-heptyl-(1-methyl-2-phenyl-ethyl)-amine 
• 60-15-1 2-amino-1-phenylpropane 
• 72687-64-0 N-ethyl-N-(1-phenylpropan-2-yl)acetamide 
• 67293-31-6 3,4,5-Trimethoxy-benzoesaeure-4-< N-ethyl-N-( 1-methyl-phenethyl )-amino>-butylester 
• 98132-98-0 N-Ethyl-N-(4-hydroxy-butyl)-1-methyl-phenethylamin 
• 52271-37-1 N-Ethyl-N-(1-methyl-2-phenyl-ethyl)-hydroxylamine 
• 29902-40-7 ethyl-(1-methyl-2-phenyl-ethyl)-(7-nitro-benzo[1,2,5]oxadiazol-4-yl)-amine 
• 93992-35-9 N-Ethyl-N-( 1-methyl-phenethyl )-bernsteinsaeure-ethylester-amid 

Relevant academic research and scientific papers

Direct Reductive N-Functionalization of Aliphatic Nitro Compounds

The first general protocol for the direct reductive N-functionalization of aliphatic nitro compounds is presented. The nitro group is partially reduced to a nitrenoid, with a mild and readily available combination of B2pin2 and zinc organyls. Thereby, the formation of an unstable nitroso intermediate is avoided, which has so far severely limited reductive transformations of aliphatic nitro compounds. The reaction is concluded by an electrophilic amination of zinc organyls.

Derivatives, immunogens, and antibodies for detecting ecstasy-class drugs

Compounds including haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives are described. Antibodies specific for the methylenedioxy class of amphetamine derivatives, reagent kits containing antibodies specific for the methylenedioxy class of amphetamine derivatives, methods of producing antibodies specific for the methylenedioxy class of amphetamine derivatives, and methods of detecting analytes including members of the methylenedioxy class of amphetamine derivatives are also described.

Antibodies for detecting ecstasy-class analytes

Compounds including haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives are described. Antibodies specific for the methylenedioxy class of amphetamine derivatives, reagent kits containing antibodies specific for the methylenedioxy class of amphetamine derivatives, methods of producing antibodies specific for the methylenedioxy class of amphetamine derivatives, and methods of detecting analytes including members of the methylenedioxy class of amphetamine derivatives are also described.

Derivatives of amphetamine, antibodies against said derivatives, reagent kits, methods of producing said antibodies, and methods of detecting said derivatives

Compounds including haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives are described. Antibodies specific for the methylenedioxy class of amphetamine derivatives, reagent kits containing antibodies specific for the methylenedioxy class of amphetamine derivatives, methods of producing antibodies specific for the methylenedioxy class of amphetamine derivatives, and methods of detecting analytes including members of the methylenedioxy class of amphetamine derivatives are also described.

Antibodies for detecting amphetamine derivatives

Compounds including haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives are described. Antibodies specific for the methylenedioxy class of amphetamine derivatives, reagent kits containing antibodies specific for the methylenedioxy class of amphetamine derivatives, methods of producing antibodies specific for the methylenedioxy class of amphetamine derivatives, and methods of detecting analytes including members of the methylenedioxy class of amphetamine derivatives are also described.

Selected reductions of conjugated nitroalkenes

Conjugated nitroalkenes are readily reduced by a variety of borane and borohydride reagents. The reactions provide a convenient access to a number of nitrogen and oxygen based functional groups.

Electron Transfer in Competition with Loss of Nitrogen in Photochemical Reactions of Aryldiazomethane with Diethylamine

The photolysis of aryldiazomethanes was studied as a function of aryl substituents and the p-nitro group was found to exert a special effect of product distribution.

Quantitative structure-activity relationships in drug metabolism and disposition: Pharmacokinetics of N-substituted amphetamines in humans

Pharmacokinetic data of 15 N-alkyl-substituted amphetamines in humans have been the object of a retrospective quantitative structure-activity relationship study. The urinary excretion of amphetamines was shown to decrease with increasing lipophilicity; the correlation equations revealed that, for identical lipophilicities, tertiary amines are excreted faster than secondary amines, which are secreted faster than primary amines. The apparent n-heptane-pH 7.4 buffer partition coefficient correlates better with urinary excretion than does the true n-octanol-water partition coefficient, probably because it includes a pKa term that accounts for the fraction of the drug present in the tubules as nonionic species. The N-dealkylation rate increases with increasing lipophilicity of the substrates (enhanced enzyme affinity) but decreases with increasing bulk of the N-substituent that is split off (steric hindrance of initial C(α)-hydroxylation.